Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Vertex Pharmaceuticals Incorporated
  6. Summary
    VRTX   US92532F1003

VERTEX PHARMACEUTICALS INCORPORATED

(VRTX)
  Report
Delayed Nasdaq  -  04:00:00 2023-06-05 pm EDT
334.42 USD   +0.19%
05/30Interview - Cheri Nel, the Investment Banker From Joburg Taking On Pharma Over Cystic Fibrosis Medicines
AQ
05/30Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 13
BU
05/09Insider Sell: Vertex Pharmaceuticals Inc
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/30/2023 05/31/2023 06/01/2023 06/02/2023 06/05/2023 Date
325.3(c) 323.57(c) 323.62(c) 333.78(c) 334.42 Last
1 888 327 5 592 332 1 342 900 1 572 791 1 044 494 Volume
-1.42% -0.53% +0.02% +3.14% +0.19% Change
More quotes
Estimated financial data (e) (USD)
Sales 2023 9 768 M - -
Net income 2023 3 431 M - -
Net cash position 2023 14 031 M - -
P/E ratio 2023 25,3x
Yield 2023 -
Sales 2024 10 491 M - -
Net income 2024 3 883 M - -
Net cash position 2024 17 805 M - -
P/E ratio 2024 22,7x
Yield 2024 -
Capitalization 85 966 M 85 966 M -
EV / Sales 2023 7,36x
EV / Sales 2024 6,50x
Nbr of Employees 4 800
Free-Float 99,5%
More Financials
Company
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (63.8%), Europe (30.3%) and other (5.9%). 
Read more
Sector
Biotechnology & Medical Research
Calendar
06/13 | 05:40pmPresentation
More about the company
Ratings of Vertex Pharmaceuticals Incorporated
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about VERTEX PHARMACEUTICALS INCORPORATED
05/30Interview - Cheri Nel, the Investment Banker From Joburg Taking On Pharma Over Cystic F..
AQ
05/30Vertex to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference on ..
BU
05/09Insider Sell: Vertex Pharmaceuticals Inc
MT
05/09Insider Sell: Vertex Pharmaceuticals Inc
MT
05/09Transcript : Vertex Pharmaceuticals Incorporated Presents at Bank of America ..
CI
05/08In-Depth - How Cystic Fibrosis Is Being Treated in SA While Breakthrough Meds Remain Ou..
AQ
05/04Piper Sandler Assumes Vertex Pharmaceuticals at Overweight With $385 Price Target
MT
05/04Vertex Pharmaceuticals Incorporated : Confirms growt..
MS
05/04Vertex Announces U.S. FDA Approval for KALYDECO to Treat Eligible Infants with CF Ages ..
AQ
05/03Vertex Announces U.S. FDA Approval for KALYDECO® (ivacaftor) to Treat Eligible Infants ..
BU
05/03Vertex Pharmaceuticals Incorporated Announces U.S. FDA Approval for Kalydeco to Treat E..
CI
05/03Maxim Adjusts Price Target on Vertex Pharmaceuticals to $400 From $325, Maintains Buy R..
MT
05/03Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $363 From $344, Maintains O..
MT
05/02VERTEX PHARMACEUTICALS INC / MA Management's Discussion and Analysis of Financial Cond..
AQ
05/02UBS Adjusts Vertex Pharmaceuticals Price Target to $399 From $375, Maintains Buy Rating
MT
More news
News in other languages on VERTEX PHARMACEUTICALS INCORPORATED
03:41aValores destacados al cierre del mercado norteamericano
05/09Vente d'initié : Vertex Pharmaceuticals Inc
05/09Vente d'initié : Vertex Pharmaceuticals Inc
05/09Compañías que se deben tener muy en cuenta por técnico este martes en Wall Street
05/05Vertex Pharmaceuticals Incorporated: Wachstumspfad b..
More news
Analyst Recommendations on VERTEX PHARMACEUTICALS INCORPORATED
More recommendations
ETFs positioned on VERTEX PHARMACEUTICALS INCORPORATEDETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
VanEck Genomics and Healthcare Innovators - USD8.11%3.64%-NC
IShares Nasdaq US Biotechnology - USD7.55%1.11%United_States
IShares Biotechnology ETF - USD7.33%1.49%-NC
VanEck Biotech ETF - USD7.31%1.42%United_States
IShares Nasdaq US Biotechnology (D) - USD7.25%1.21%United_States
More ETFs positioned on VERTEX PHARMACEUTICALS INCORPORATED
Analysis
Vertex Pharmaceuticals Incorporated : Confirms growth trajectory
Stock Pick
 VERTEX PHARMACEUTICALS
A very promising pipeline
Chart VERTEX PHARMACEUTICALS INCORPORATED
Duration : Period :
Vertex Pharmaceuticals Incorporated Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VERTEX PHARMACEUTICALS INCORPORATED
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 32
Last Close Price 333,78 $
Average target price 372,14 $
Spread / Average Target 11,5%
EPS Revisions
Managers and Directors
Reshma Kewalramani President, Chief Executive Officer & Director
Charles F. Wagner Chief Financial Officer & Executive Vice President
Jeffrey M. Leiden Executive Chairman
David Matthew Altshuler Chief Scientific Officer & EVP-Global Research
Carmen Bozic Chief Medical Officer & EVP-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
VERTEX PHARMACEUTICALS INCORPORATED15.58%85 966
REGENERON PHARMACEUTICALS, INC.2.56%79 256
WUXI APPTEC CO., LTD.-16.25%28 067
BIONTECH SE-28.02%26 058
GENMAB A/S-7.45%25 588
BEIGENE, LTD.3.37%23 787
MarketScreener: Created by Investors for Investors!
100% Free Registration
fermer